You are here

  • Home
  • Online First
  • METAVISION: a novel system for quantifying metamorphopsia in patients with myopic traction maculopathy

Article Text

Article menu
Download PDFPDF
Retina
METAVISION: a novel system for quantifying metamorphopsia in patients with myopic traction maculopathy
  1. Qi Zhang1,
  2. Xiujuan Zhao1,
  3. Xia Huang1,
  4. Qingxiu Wu1,
  5. Shida Chen1,
  6. Yonghao Li2,
  7. Ping Lian1,
  8. Lin Lu1
  1. 1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, Guangdong, China
  2. 2Guangzhou Aier Eye Hospital, Guangzhou, Guangdong, China
  1. Correspondence to Dr Lin Lu, Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China; lulin888{at}126.com; Dr Ping Lian; lianping{at}gzzoc.com

Abstract

Purpose To develop a novel system for quantifying metamorphopsia in patients with myopic traction maculopathy (MTM) and to explore the metamorphopsia pattern of MTM.

Design Observational, cross-sectional study.

Methods We designed a new system.

Results Of the 445 eyes tested, 188 (42.25%) were deemed by patients to have metamorphopsia impacting their daily lives while 257 (57.75%) were considered to have no metamorphopsia symptoms. The Amsler grid, M-CHARTS and METAVISION tests displayed sensitivities for metamorphopsia of 95.74%, 89.89% and 100%, respectively. The specificities of the Amsler grid, M-CHARTS and METAVISION tests are 100%. The metamorphopsia questionnaire and METAVISION scores were highly consistent (average intraclass correlation coefficient=0.951, p<0.001) and strongly correlated (R=0.879, p<0.001). The METAVISION score was highly correlated with the stages of MTM (R=0.837, p<0.001), whereas there was a moderate correlation between the M-CHARTS M-score and the stages of MTM (R=0.679, p<0.001).

Conclusions Quantification of metamorphopsia is important and useful for MTM management. The METAVISION is a clinically applicable and comprehensive approach for quantifying metamorphopsia, which can be used in clinical settings.

  • Retina
  • Pathology

Data availability statement

Data are available on reasonable request. No data are available. Not applicable.

https://doi.org/10.1136/bjo-2023-324175

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available on reasonable request. No data are available. Not applicable.

    View Full Text

    Footnotes

    • QZ and XZ contributed equally.

    • Correction notice This article has been updated since it was first published. A funding statement has been added.

    • Contributors QZ and LL designed the metamorphopsia system. XH and QW collected clinical data and edited images. XZ, PL and YL wrote the statistical analysis plan, cleaned and analysed the data, and drafted and revised the paper. LL, PL and SC initiated this study, implemented the study and revised the draft paper. LL is guarantor. All authors read and approved the final manuscript.

    • Funding This research was supported by the Innovative Clinical Technique of Guangzhou (2024P-GX02), Science and Technology Program of Guangzhou, China (202201020362, 2024A03J0257), and from the Lumitin Vision to Brightness Research Funding for the Young and middle-aged Ophthalmologists (BCF-KH-YK-20230803-03). The sponsor or funding organisation had no role in the design or conduct of this research.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.